-
Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes.
Journal of ImmunologyRieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum CJ, Concannon P, Buckner JH -
Role of insulin resistance in predicting progression to type 1 diabetes.
Diabetes CareXu P, Cuthbertson D, Greenbaum CJ, Palmer JP, Krischer JP, Diabetes Prevention Trial Type 1 Study Group. -
Editorial: The role of glucagon in postprandial hyperglycemia--the jury's still out.
J Clin Endocrinol MetabBollyky J, Greenbaum CJ -
International comparison of C-peptide measurements.
Clinical ChemistryWiedmeyer HM, Polonsky KS, Myers GL, Little RR, Greenbaum CJ, Goldstein DE, Palmer JP -
Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1.
Diabetes CareSosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS, Diabetes Prevention Trial-Type 1 Study Group. -
Identification of Novel HLA-A*0201-restricted epitopes in recent-onset type 1 diabetic subjects and antibody-positive relatives.
DiabetesStandifer NE, Ouyang Q, Panagiotopoulos C, Verchere CB, Tan R, Greenbaum CJ, Pihoker C, Nepom GT -
Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study.
DiabetesSeyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC -
Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes.
The Journal of Clinical Endocrinology and MetabolismRedondo MJ, Babu S, Zeidler A, Orban T, Yu L, Greenbaum CJ, Palmer JP, Cuthbertson DD, Eisenbarth GS, Krischer JP, Schatz DA, Diabetes Prevention Trial Type 1 Study Group. -
Progress, but not yet ready for clinical use: interrupting immune-mediated destruction of pancreatic beta cells in type 1 diabetes.
Current Diabetes ReportsGreenbaum CJ -
Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1.
Diabetes CareSosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS -
Evaluation of leptin levels in subjects at risk for type 1 diabetes.
J AutoimmunGilliam LK, Jensen RA, Yang P, Weigle DS, Greenbaum CJ, Pihoker C -
Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects.
Journal of ImmunologyYang J, Danke NA, Berger D, Reichstetter S, Reijonen H, Greenbaum CJ, Pihoker C, James EA, Kwok WW -
Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope.
Scand J ImmunolAlleva DG, Maki RA, Putnam AL, Robinson JM, Kipnes MS, Dandona P, Marks JB, Simmons DL, Greenbaum CJ, Jimenez RG, Conlon PJ, Gottlieb PA -
Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects.
Journal of AutoimmunityDanke NA, Yang J, Greenbaum CJ, Kwok WW -
Latent autoimmune diabetes in adults (LADA) should be less latent.
DiabetologiaFourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, Harrison LC
